STOCK TITAN
  1. Home
  2. News
  3. BTMD

Biote Corp. - BTMD STOCK NEWS

Welcome to our dedicated page for Biote news (Ticker: BTMD), a resource for investors and traders seeking the latest updates and insights on Biote stock.

Biote Corp. (BTMD) operates in the specialized field of hormone optimization, offering growth practice-building solutions. The company's primary focus is to empower Biote-certified practitioners with the tools and knowledge required to establish, build, and effectively implement hormone optimization programs. These programs are designed to provide personalized solutions tailored to individual patient needs.

Biote Corp. provides a comprehensive suite of components to its practitioners, including training, marketing support, and ongoing education. This holistic approach ensures that practitioners are well-equipped to deliver high-quality care in the hormone optimization space. The company's commitment to education and support is a key differentiator, enabling practitioners to stay at the forefront of this rapidly evolving field.

Recent achievements by Biote Corp. include expanding its network of certified practitioners and forging new partnerships aimed at enhancing its service offerings. The company continues to invest in research and development to improve its products and services, ensuring that they meet the highest standards of efficacy and safety.

Financially, Biote Corp. has demonstrated steady growth, driven by the increasing demand for hormone optimization solutions. The company's strategic initiatives and robust business model have positioned it well to capitalize on emerging opportunities in the healthcare sector.

For those interested in the latest updates and developments from Biote Corp., the company regularly releases news and updates, which are accessible through various channels.

News

Biote Schedules Fourth Quarter and Full Year 2023 Financial Results Release and Conference Call

Rhea-AI Summary
Biote Corp. (BTMD) announces the release of its fourth-quarter and full-year financial results on March 12, 2024, followed by a conference call to discuss the outcomes. The company focuses on personalized hormone optimization and therapeutic wellness solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.76%
Tags
earnings
-
News

Biote Announces Agreement to Resolve Litigation and Repurchase All of Founder’s Shares

Rhea-AI Summary
Biote Corp. (BTMD) announces the repurchase of approximately 18.4 million Class A shares and Paired Interests at $4.17 per share, resolving litigation with founder Dr. Gary S. Donovitz. The settlement includes mutual claims release, non-compete agreements, and a voting agreement. The repurchase, totaling $76.9 million, aims to enhance shareholder value and strengthen Biote's position in therapeutic wellness.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.13%
Tags
buyback
-
News

Biote Announces $20 Million Share Repurchase Authorization

Rhea-AI Summary
Biote Corp. (BTMD) has announced a $20 million share repurchase program, marking the company's first authorization for share repurchases. The program grants management the authority to repurchase outstanding shares of the common stock through various means. CEO Terry Weber expressed confidence in the company's growth opportunity and business outlook, citing a strong balance sheet to support opportunistic share repurchases. The timing and extent of repurchases will be at the discretion of management, with no obligation to repurchase any specific amount or number of shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.36%
Tags
buyback
News

Biote to Purchase Asteria Health

Rhea-AI Summary
Biote Corp. (BTMD) has announced the acquisition of F.H. Investments, Inc., d/b/a Asteria Health, a 503B manufacturer of compounded bioidentical hormones, for a purchase price of $8.5 million. The acquisition is expected to strengthen Biote's control over its supply chain, enhance efficiency, and provide expertise in 503B manufacturing. The transaction is anticipated to have minimal near-term revenue impact on Biote, with the potential for additional payments to Asteria Health shareholders based on production metrics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.61%
Tags
none
-
News

Biote Provides Preliminary 2023 Results and Initial 2024 Guidance

Rhea-AI Summary
Biote Corp. (BTMD) expects 2023 revenue and Adjusted EBITDA to be slightly below prior guidance, with revenue of $185-$187 million and Adjusted EBITDA of $54-$56 million. The 2023 revenue growth is expected to be approximately 12% over the prior year, with procedure revenue growth of 9% and dietary supplement revenue growth of 17%. The expected fourth quarter revenue includes procedure revenue growth of 7% and dietary supplement revenue decline of 15% compared to the same period in 2022. The decline in dietary supplement revenue was due to one of Biote’s larger distributors exiting the nutraceutical business. The company also provided initial 2024 financial guidance, projecting revenue of greater than $200 million and Adjusted EBITDA of greater than $60 million, with expected modest contributions from new therapeutic wellness products and the acquisition of Asteria Health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.61%
Tags
none
-
News

Biote Names Robert Peterson as Chief Financial Officer

Rhea-AI Summary
Biote Corp. (BTMD) announces Robert Peterson as new Chief Financial Officer, bringing 15 years of health and wellness industry experience and public company experience. Peterson will lead finance operations, including accounting, financial planning, and analysis. The transition is unrelated to financial results or disagreements. CEO Terry Weber expresses gratitude to outgoing CFO Samar Kamdar and looks forward to maximizing growth opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
none
News

Biote Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
Biote (NASDAQ: BTMD) Achieves Progress in Test of Complementary Wellness Therapeutics, Reiterates 2023 Financial Guidance. Biote reported a 8.5% increase in revenue to $45.6 million and a 70-basis point increase in gross profit margin to 68.9%. Net income rose to $19.6 million with a net income margin of 43.1%. Adjusted EBITDA increased by 14.7% to $14.0 million with a margin of 30.8%. The company also reiterated their 2023 guidance range of $190-$200 million in revenue and $56-$60 million in Adjusted EBITDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.75%
Tags
earnings
-
News

Biote Schedules Third Quarter 2023 Financial Results Release and Conference Call

Rhea-AI Summary
Biote Corp. will release its third quarter financial results on November 7, 2023, followed by a conference call on November 8, 2023, to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.8%
Tags
earnings
-
News

Biote Reports Second Quarter 2023 Financial Results

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.43%
Tags
earnings
News

Biote Schedules Second Quarter 2023 Financial Results Release and Conference Call

Rhea-AI Summary
Biote Corp. will release their second quarter financial results on August 10, 2023, followed by a conference call on August 11, 2023. The conference call details and webcast link are provided in the PR.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.74%
Tags
earnings

FAQ

What is the current stock price of Biote (BTMD)?

The current stock price of Biote (BTMD) is $6.1 as of December 20, 2024.

What is the market cap of Biote (BTMD)?

The market cap of Biote (BTMD) is approximately 179.2M.

What does Biote Corp. do?

Biote Corp. operates in the hormone optimization space, providing tools and support for practitioners to implement personalized hormone optimization programs.

Who are Biote-certified practitioners?

Biote-certified practitioners are healthcare professionals trained and certified by Biote Corp. to deliver hormone optimization solutions.

What kind of support does Biote Corp. provide to practitioners?

Biote Corp. offers training, marketing support, and ongoing education to ensure practitioners can successfully implement hormone optimization programs.

What recent achievements has Biote Corp. made?

Recent achievements include expanding its network of practitioners and forging new partnerships to enhance service offerings.

How does Biote Corp. ensure the quality of its hormone optimization solutions?

Biote Corp. invests in research and development to continually improve the efficacy and safety of its products and services.

What is Biote Corp.'s financial condition?

Biote Corp. has shown steady growth driven by the increasing demand for hormone optimization solutions and strategic business initiatives.

How can I stay updated on Biote Corp.'s latest news?

Biote Corp. regularly releases news and updates, available through various channels to keep interested parties informed.

What are the core components provided by Biote Corp. to practitioners?

Biote Corp. provides training, marketing support, and ongoing education as part of its comprehensive suite of components for practitioners.

Why is hormone optimization important?

Hormone optimization is important for maintaining balance in the body, which can improve overall health and well-being.

Who can benefit from Biote Corp.'s hormone optimization programs?

Patients seeking personalized hormone optimization to address their specific health needs can benefit from Biote Corp.'s programs.

Stock BTMD logo
Biote Corp.

Nasdaq:BTMD

BTMD Rankings

#3956 Ranked by Market Cap
N/A Ranked by Dividends

BTMD Stock Data

179.21M
23.67M
27.6%
64.61%
2.65%
Medical Care Facilities
Medicinal Chemicals & Botanical Products
Link
United States of America
IRVING